Who Buys Amiodarone from India — 411 Importers Behind a $74.6M Market

The importation of Amiodarone from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like UNICHEM PHARMACEUTICALS (USA) INC. and EVERSANA LIFE SCIENCES SERVICES LLC in the United States fall into this category. They procure large volumes to supply hospitals, pharmacies, and healthcare providers, often placing regular, sizable orders to maintain a steady supply chain.

• Hospital Groups: While not explicitly listed among the top buyers, hospital groups typically purchase Amiodarone directly for in-house use, focusing on consistent supply to meet patient needs.

• Retail Chains: Pharmacy chains may import Amiodarone to stock their outlets, ensuring availability for prescriptions. Their orders are usually based on consumer demand and prescription trends.

• Government Procurement: Organizations like M/S. RANBAXY FARMACEUTICA LTDA in Brazil may engage in government tenders to supply public healthcare systems, often involving bulk purchases through competitive bidding processes.

• Re-exporters: Companies such as WOODFIELD DISTRIBUTION LLC in the United States might import Amiodarone for redistribution to other markets, leveraging their logistical networks to serve regions beyond their primary location.

• Contract Manufacturers: Some buyers may act as contract manufacturers, importing Amiodarone as an active pharmaceutical ingredient (API) for formulation into finished products, adhering to specific client requirements.

Understanding these segments aids in tailoring marketing strategies and supply chain logistics to meet the unique demands of each buyer type.

United States

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process: Importers must ensure that Amiodarone complies with FDA regulations, including facility registration, product listing, and adherence to Current Good Manufacturing Practices (CGMP).

3. Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and FDA review times.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the United States.

Brazil

1. Drug Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).

2. Import Registration Process: Importers must obtain ANVISA approval, which includes product registration, compliance with Brazilian pharmacopoeia standards, and local testing requirements.

3. Estimated Timeline for Registration: The process typically takes 6 to 12 months, subject to ANVISA's evaluation and any additional information requests.

4. Import Tariff/Duty for HS 30049099: Brazil imposes a standard import duty of 14% on pharmaceutical products under this HS code.

Thailand

1. Drug Regulatory Authority: Thai Food and Drug Administration (Thai FDA).

2. Import Registration Process: Requires submission of a comprehensive dossier, including clinical data, manufacturing details, and labeling information, followed by Thai FDA evaluation.

3. Estimated Timeline for Registration: Approximately 12 to 18 months, depending on the complexity of the application and regulatory review.

4. Import Tariff/Duty for HS 30049099: Thailand applies a 10% import duty on pharmaceutical products classified under this HS code.

Venezuela

1. Drug Regulatory Authority: Instituto Nacional de Higiene Rafael Rangel (INHRR).

2. Import Registration Process: Involves product registration with INHRR, including submission of quality, safety, and efficacy data, along with compliance with local labeling regulations.

3. Estimated Timeline for Registration: The process can extend beyond 12 months due to bureaucratic procedures and potential delays.

4. Import Tariff/Duty for HS 30049099: Venezuela's import duties vary; specific rates for HS code 30049099 should be confirmed with local customs authorities.

Germany

1. Drug Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).

2. Import Registration Process: Requires marketing authorization from BfArM, including submission of a Common Technical Document (CTD) and adherence to European Union regulations.

3. Estimated Timeline for Registration: Typically 7 to 12 months, contingent on the completeness of the application and BfArM's review process.

4. Import Tariff/Duty for HS 30049099: As part of the European Union, Germany applies a 0% import duty on pharmaceutical products under this HS code.

The demand for Amiodarone is primarily driven by the prevalence of cardiovascular diseases (CVDs), which remain a leading cause of mortality worldwide. According to the World Health Organization (WHO), CVDs account for over 17 million deaths annually, underscoring the critical need for effective antiarrhythmic medications like Amiodarone.

Government healthcare programs and the expansion of universal health coverage (UHC) further bolster demand. Many countries have integrated Amiodarone into their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which includes Amiodarone as a complementary medicine for priority diseases requiring specialized care. This inclusion facilitates procurement through tender-based purchasing systems, ensuring broader access and affordability. The presence of 411 buyers across 124 countries, as per TransData Nexus data, reflects a robust global market and significant opportunities for suppliers to meet the ongoing and expanding needs for Amiodarone.

The importation of Amiodarone from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like UNICHEM PHARMACEUTICALS (USA) INC. and EVERSANA LIFE SCIENCES SERVICES LLC in the United States fall into this category. They procure large volumes to supply hospitals, pharmacies, and healthcare providers, often placing regular, sizable orders to maintain a steady supply chain.

• Hospital Groups: While not explicitly listed among the top buyers, hospital groups typically purchase Amiodarone directly for in-house use, focusing on consistent supply to meet patient needs.

• Retail Chains: Pharmacy chains may import Amiodarone to stock their outlets, ensuring availability for prescriptions. Their orders are usually based on consumer demand and prescription trends.

• Government Procurement: Organizations like M/S. RANBAXY FARMACEUTICA LTDA in Brazil may engage in government tenders to supply public healthcare systems, often involving bulk purchases through competitive bidding processes.

• Re-exporters: Companies such as WOODFIELD DISTRIBUTION LLC in the United States might import Amiodarone for redistribution to other markets, leveraging their logistical networks to serve regions beyond their primary location.

• Contract Manufacturers: Some buyers may act as contract manufacturers, importing Amiodarone as an active pharmaceutical ingredient (API) for formulation into finished products, adhering to specific client requirements.

Understanding these segments aids in tailoring marketing strategies and supply chain logistics to meet the unique demands of each buyer type.

United States

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process: Importers must ensure that Amiodarone complies with FDA regulations, including facility registration, product listing, and adherence to Current Good Manufacturing Practices (CGMP).

3. Estimated Timeline for Registration: The registration process can take several months, depending on the completeness of the application and FDA review times.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the United States.

Brazil

1. Drug Regulatory Authority: Agência Nacional de Vigilância Sanitária (ANVISA).

2. Import Registration Process: Importers must obtain ANVISA approval, which includes product registration, compliance with Brazilian pharmacopoeia standards, and local testing requirements.

3. Estimated Timeline for Registration: The process typically takes 6 to 12 months, subject to ANVISA's evaluation and any additional information requests.

4. Import Tariff/Duty for HS 30049099: Brazil imposes a standard import duty of 14% on pharmaceutical products under this HS code.

Thailand

1. Drug Regulatory Authority: Thai Food and Drug Administration (Thai FDA).

2. Import Registration Process: Requires submission of a comprehensive dossier, including clinical data, manufacturing details, and labeling information, followed by Thai FDA evaluation.

3. Estimated Timeline for Registration: Approximately 12 to 18 months, depending on the complexity of the application and regulatory review.

4. Import Tariff/Duty for HS 30049099: Thailand applies a 10% import duty on pharmaceutical products classified under this HS code.

Venezuela

1. Drug Regulatory Authority: Instituto Nacional de Higiene Rafael Rangel (INHRR).

2. Import Registration Process: Involves product registration with INHRR, including submission of quality, safety, and efficacy data, along with compliance with local labeling regulations.

3. Estimated Timeline for Registration: The process can extend beyond 12 months due to bureaucratic procedures and potential delays.

4. Import Tariff/Duty for HS 30049099: Venezuela's import duties vary; specific rates for HS code 30049099 should be confirmed with local customs authorities.

Germany

1. Drug Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).

2. Import Registration Process: Requires marketing authorization from BfArM, including submission of a Common Technical Document (CTD) and adherence to European Union regulations.

3. Estimated Timeline for Registration: Typically 7 to 12 months, contingent on the completeness of the application and BfArM's review process.

4. Import Tariff/Duty for HS 30049099: As part of the European Union, Germany applies a 0% import duty on pharmaceutical products under this HS code.

The demand for Amiodarone is primarily driven by the prevalence of cardiovascular diseases (CVDs), which remain a leading cause of mortality worldwide. According to the World Health Organization (WHO), CVDs account for over 17 million deaths annually, underscoring the critical need for effective antiarrhythmic medications like Amiodarone.

Government healthcare programs and the expansion of universal health coverage (UHC) further bolster demand. Many countries have integrated Amiodarone into their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which includes Amiodarone as a complementary medicine for priority diseases requiring specialized care. This inclusion facilitates procurement through tender-based purchasing systems, ensuring broader access and affordability. The presence of 411 buyers across 124 countries, as per TransData Nexus data, reflects a robust global market and significant opportunities for suppliers to meet the ongoing and expanding needs for Amiodarone.